Evaluating Pharmaceuticals for Health Policy and Reimbursement

“The challenge in all settings is to make the difficult decisions in a way that is defensible, justifiable, ethical, and equitable”

So write Nick Freemantle and Suzanne Hill in their introduction to this important discussion on decision making in the reimbursement of pharmaceuticals. Based around a programme supported by the World Health Organization, chapters by leading academics involved in the research tackle such major issues as international pharmaceutical policy, tensions in licensing policies, priority setting, and relationships between the stakeholders.

Chapters include

Development of marketing authorisation procedures for pharmaceuticals
Interpreting clinical evidence
International pharmaceutical policy: health creation or wealth creation?
Development of fourth hurdle policies around the world
Economic modelling in drug reimbursement
Priority setting in health care: matching decision criteria with policy objectives
Tensions in licensing and reimbursement decisions: case of riluzole for amytrophic lateral sclerosis
Relationship between stakeholders: managing the war of words
Medicine and the media: good information or misleading hype?
How to promote quality use of cost–effective medicines
Using economic evaluation to inform health policy and reimbursement: making it happen and making it sustainable
Pricing of pharmaceuticals
Evaluating pharmaceuticals for health policy in low and middle income country settings.

Besides the controversial issues there is a wealth of practical information including economic modelling and the experiences from the WHO programme, providing readers with workable examples. This is essential reading for clinical researchers in pharmaceuticals and policy makers everywhere.

Spis treści:
Introduction.< br>Development of marketing authorisation procedures for pharmaceuticals.
Interpreting clinical evidence.
International pharmaceutical policy – health creation or wealth creation?.
The development of fourth hurdle policies around the world.
Economic modelling in drug reimbursement.
Priority–setting in health care: matching decision criteria with policy objectives.
The tensions in licensing and reimbursement decisions: the case of riluzole for amyotrophic lateral.
sclerosis.
Relationship between stakeholders: managing the war of the words.
Medicines and the media: good information or misleading hype?.
How to promote quality use of cost–effective medicines.
Making it happen and making it sustainable.
Pricing of pharmaceuticals.
Evaluating pharmaceuticals for health policy in low and middle income country settings

Okładka tylna:
“The challenge in all settings is to make the difficult decisions in a way that is defensible, justifiable, ethical, and equitable”

So write Nick Freemantle and Suzanne Hill in their introduction to this important discussion on decision making in the reimbursement of pharmaceuticals. Based around a programme supported by the World Health Organization, chapters by leading academics involved in the research tackle such major issues as international pharmaceutical policy, tensions in licensing policies, priority setting, and relationships between the stakeholders.

Chapters include

Development of marketing authorisation procedures for pharmaceuticals
Interpreting clinical evidence
International pharmaceutical policy: health creation or wealth creation?
Development of fourth hurdle policies around the world
Economic modelling in drug reimbursement
Priority setting in health care: matching decision criteria with policy objectives
Tensions in licensing an d reimbursement decisions: case of riluzole for amytrophic lateral sclerosis
Relationship between stakeholders: managing the war of words
Medicine and the media: good information or misleading hype?
How to promote quality use of cost–effective medicines
Using economic evaluation to inform health policy and reimbursement: making it happen and making it sustainable
Pricing of pharmaceuticals
Evaluating pharmaceuticals for health policy in low and middle income country settings.

Besides the controversial issues there is a wealth of practical information including economic modelling and the experiences from the WHO programme, providing readers with workable examples. This is essential reading for clinical researchers in pharmaceuticals and policy makers everywhere.